Carotid & Intracranial Stenosis Prevention
Carotid & Intracranial Stenosis Prevention
There is no way of living that reverses an established narrowing, and it is worth saying so before listing anything. What there is, is a treatment that substantially lowers the chance of the narrowing causing an event, and a follow-up arrangement that catches the change that would reopen the decision. Both of those are active tasks with targets and dates attached, and both are more often underdone than the procedures that get the attention. This page is about what each one should actually contain.
The prevention is the medication
This is the part of the page that matters most and the part most often treated as background. In this condition, prevention is not a leaflet about eating and exercise given alongside a prescription. The prevention is the medication, taken properly and to targets, indefinitely.
What that means in practice is specific. An antiplatelet agent, chosen and continued rather than stopped after a period because nothing has happened. A statin, dosed to reach a lipid target and adjusted when it does not, with another agent added where the statin alone is insufficient. Blood pressure treated to the target that applies now rather than the one that applied when the patient was first treated. Diabetes treated as part of the same vascular plan. And smoking stopped, with support rather than advice.
The reason for labouring this is that the gap between what is prescribed and what is achieved is large, and it is where the preventable events come from. A patient on a statin whose lipid level has never been checked since the prescription was written is not on statin therapy in any meaningful sense. A patient whose blood pressure is controlled to a number that was a target twenty years ago is not controlled.
And it applies after a procedure as much as before one. The operation treats a lesion; the medication treats the disease. Patients are sometimes left with the impression that the carotid has been dealt with and the tablets are now optional, which is the wrong way round.
Blood pressure: the one most often undertreated
Of everything on this page, blood pressure is both the most consistently identified driver of carotid and intracranial disease and the one most often treated to a target that has been superseded. It is also the one a patient can measure themselves, which makes it the most actionable item on the list.
What makes a difference is the method. A single reading taken in a clinic, in a patient who is anxious and has just walked in, is a weak piece of information. A week of readings taken at home, at the same times, sitting quietly with the arm supported, is a strong one. Two readings each morning and each evening for a week, written down, tell a clinician more than any number measured in a corridor.
What also matters is that the target is a moving thing and has moved downwards over the years. A patient whose blood pressure has been described as fine for a decade may be above the level that would now be aimed for, and finding that out is worth more than any additional investigation. It is reasonable to ask what the target is and what the home readings have been.
Lipids: a target, not a dose
The way statin therapy is meant to work in this condition is by reaching a level, not by taking a tablet. The dose is adjusted to reach the level, the level is measured to check it has been reached, and where a statin alone does not get there, another agent is added rather than the target being quietly abandoned.
What patients are often told is that they are on a statin. What is worth knowing is what the low-density lipoprotein cholesterol level is, what it is supposed to be in someone with established large-vessel disease, and whether the gap is being closed. Those three numbers are the whole of the conversation.
Two practical points that come up repeatedly. Muscle symptoms are the commonest reason patients stop a statin, and most of what is attributed to the drug is not caused by it — but it should be investigated rather than either dismissed or accepted, because there are options, including a different agent, a different dose, and additional non-statin therapy. And where a patient has stopped a statin because the scan has not changed, the reasoning is backwards: the scan is not what the treatment is for.
Smoking: the largest single change available
Smoking acts on this condition through more than one route at once — on the lining of the vessel directly, and on how readily the blood clots — and stopping is the single change with the largest effect. It is also the one most often handed to the patient to achieve alone, which is the least effective way to do it.
What works better than advice is treatment: combined support and medication rather than either alone, a date rather than a gradual reduction, and follow-up rather than a single conversation. Former smokers carry more risk than people who never smoked, which is worth saying plainly, and the risk falls progressively after stopping rather than returning to baseline immediately — both of which are reasons to say so rather than to imply that the damage is either permanent or instantly undone.
Follow-up: what imaging catches, and how often
The purpose of follow-up imaging is not to produce a number to file. It is to answer whether this narrowing is changing, because change is what reopens a decision that has been made — and the features that move a conversation are progression of the narrowing, a change in the plaque towards ulceration, and new injury downstream on imaging of the brain.
One condition makes the whole exercise work: the same method each time. A percentage derived from velocities by ultrasound, from a CT angiogram, and from a catheter angiogram are not interchangeable, and a change between two of them may be a change in method rather than in the vessel. Where follow-up is by ultrasound, having it done in the same laboratory reduces the variability further.
The other side of follow-up is the other vessels. Disease on the opposite side, disease in series in the same vessel, and the coronary circulation are all part of the same condition, and a surveillance plan that looks at one carotid bifurcation and nothing else has not addressed what the patient has. Where there are several territories, one plan with dates beats several separate ones.
What a plan should contain
A plan worth having is short and has dates in it. The medication, with the targets it is aiming at and when they will be checked. The imaging, with the interval and the method. And the symptoms that bring the patient back the same day rather than at the next appointment.
Those symptoms are worth stating to the patient explicitly, because the commonest way this goes wrong is not a missed scan but a transient attack that resolved and was not reported for a week. Weakness or numbness on one side, speech lost or slurred, vision lost in one eye, double vision or difficulty swallowing, sudden severe unsteadiness with vomiting, or a sudden severe headache unlike any before — any of them, the same day.
And the plan should say what would change it. A patient who knows that progression of the narrowing, a change in the plaque, or a new event would reopen the question is in a better position than one who was told to come back in a year without being told what for. The follow-up is not reassurance; it is a way of catching the change early enough to matter.